The Food and Drug Administration (FDA), under the leadership of Commissioner Tukaram Mundhe, has issued formal legal notices to three of India’s most prominent cinema stars—Shah Rukh Khan, Ajay Devgn, and Tiger Shroff. The actors, who serve as brand ambassadors for Vimal, have been ordered to provide a detailed explanation within 15 days regarding their participation in advertising campaigns that the regulator alleges bypass laws prohibiting the promotion of tobacco and pan masala products.
The action marks a significant escalation in the regulatory crackdown on surrogate advertising, targeting the individuals who lend their public image to brands that operate in legally restricted sectors.
The Regulatory Action
The notices issued by Commissioner Tukaram Mundhe demand a formal response from the actors to justify the nature of the advertisements they have fronted for Vimal. The core of the FDA’s investigation centers on whether the promotional material constitutes “surrogate advertising”—a practice where a company promotes a prohibited product (such as pan masala or tobacco) by masquerading it as a permissible product (such as cardamom or mouth fresheners) under the same brand name.
Under current Indian law, the direct advertisement of tobacco and pan masala products is strictly prohibited due to public health concerns. However, companies frequently utilize “brand extensions” to maintain high visibility. The FDA is now scrutinizing whether the Vimal campaigns are designed to mislead the public or intentionally circumvent these statutory bans by associating the brand with non-tobacco products while relying on the consumer’s existing association of the brand with pan masala.
The 15-day deadline imposed by the FDA indicates a move toward swift administrative action, requiring the actors to clarify their role in the campaign’s conceptualization and their awareness of the regulatory boundaries governing such endorsements.
Why This Matters
This move is significant not only because of the celebrity status of the individuals involved but because it shifts the focus of accountability. Historically, regulatory actions against surrogate advertising have targeted the corporations and the advertising agencies responsible for the campaigns. By issuing notices directly to the brand ambassadors, the FDA is asserting that the faces of these campaigns share a degree of responsibility for the legality of the messaging.
The involvement of Shah Rukh Khan, Ajay Devgn, and Tiger Shroff—actors with massive influence across diverse demographics in India—means these advertisements have a profound reach. The FDA’s intervention suggests that the scale of this influence necessitates a higher standard of scrutiny, as the perceived endorsement of a brand linked to tobacco can normalize the use of such products among youth and vulnerable populations.
Analysis:
The FDA’s strategy reflects a broader institutional shift toward closing the “surrogate loophole.” For years, the tobacco and pan masala industries have operated in a gray area, using identical logos, colors, and slogans for “Elaichi” (cardamom) products as they do for their tobacco-based offerings. By targeting high-profile figures, Commissioner Mundhe is signaling that the “ignorance of the contract” defense—where celebrities claim they were merely hired to read a script for a legal product—may no longer be sufficient. This creates a new risk profile for celebrity endorsements in India, forcing actors to conduct deeper due diligence on the corporate structures and product portfolios of the brands they represent.
Background and Context
Surrogate advertising has been a persistent challenge for Indian regulators, including the Advertising Standards Council of India (ASCI) and the Ministry of Information and Broadcasting. The practice is designed to maintain “top-of-mind awareness” for a brand even when the primary product cannot be legally mentioned on television or in print.
The Vimal brand has been a frequent subject of public debate and legal scrutiny. Critics have long argued that the distinction between the “cardamom” ads and the pan masala product is a distinction without a difference, as the branding remains identical. Previous attempts to curb these ads have often resulted in minor tweaks to the wording of the commercials rather than a cessation of the practice.
Commissioner Tukaram Mundhe, known for a strict administrative approach and a history of challenging entrenched interests, appears to be applying a more aggressive interpretation of the law. His focus is on the “intent” of the advertisement—whether the primary goal is to sell a legal product or to keep a prohibited brand visible in the public consciousness.
What to Watch Next
The coming 15 days will be critical in determining the trajectory of this case. There are three primary outcomes to monitor:
First, the nature of the actors’ responses. If the legal teams for Khan, Devgn, and Shroff argue that they were promoting a legitimate, non-tobacco product as per their contracts, the FDA will have to decide if that defense holds water under the “indirect promotion” framework.
Second, the potential for a wider sweep. If the FDA finds the explanations unsatisfactory, it may lead to fines, orders to pull the advertisements from all platforms, or further legal proceedings. This could set a precedent that triggers similar notices for other celebrities associated with surrogate brands in the liquor or tobacco sectors.
Third, the industry reaction. A victory for the FDA in this instance could lead to a cooling effect on celebrity endorsements for any brand that has a prohibited product in its portfolio, potentially altering the financial landscape of celebrity branding in India.
Conclusion
The notices issued to Shah Rukh Khan, Ajay Devgn, and Tiger Shroff represent more than a routine regulatory check; they are a challenge to the established norms of the Indian advertising industry. By demanding accountability from the ambassadors themselves, the FDA is attempting to dismantle the shield of “indirect promotion” that has long protected tobacco-linked corporations. As the 15-day window closes, the resolution of this matter will likely define the future boundaries of celebrity influence and corporate accountability in the Indian marketplace.
Sources:
Hindustan Times – India News: https://www.hindustantimes.com/india-news/shah-rukh-ajay-devgn-tiger-shroff-now-get-notice-from-fdas-tukaram-mundhe-over-vimal-ad-explain-in-15-days-101786858164467.html
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: Hindustan Times – India News — source
